JPWO2022019259A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022019259A5 JPWO2022019259A5 JP2022537997A JP2022537997A JPWO2022019259A5 JP WO2022019259 A5 JPWO2022019259 A5 JP WO2022019259A5 JP 2022537997 A JP2022537997 A JP 2022537997A JP 2022537997 A JP2022537997 A JP 2022537997A JP WO2022019259 A5 JPWO2022019259 A5 JP WO2022019259A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- her2
- antibody
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020123564 | 2020-07-20 | ||
| JP2020123564 | 2020-07-20 | ||
| PCT/JP2021/026932 WO2022019259A1 (ja) | 2020-07-20 | 2021-07-19 | 抗ｈｅｒ２抗体－薬物コンジュゲートとｈｅｒ二量体化阻害剤の組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2022019259A1 JPWO2022019259A1 (https=) | 2022-01-27 |
| JPWO2022019259A5 true JPWO2022019259A5 (https=) | 2024-07-30 |
| JP7848119B2 JP7848119B2 (ja) | 2026-04-20 |
Family
ID=79728699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537997A Active JP7848119B2 (ja) | 2020-07-20 | 2021-07-19 | 抗ｈｅｒ２抗体－薬物コンジュゲートとｈｅｒ二量体化阻害剤の組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230293714A1 (https=) |
| EP (1) | EP4183420A4 (https=) |
| JP (1) | JP7848119B2 (https=) |
| KR (1) | KR20230042055A (https=) |
| CN (1) | CN115884794A (https=) |
| AU (1) | AU2021312537A1 (https=) |
| BR (1) | BR112023000982A2 (https=) |
| CA (1) | CA3186675A1 (https=) |
| IL (1) | IL300030A (https=) |
| TW (1) | TW202216214A (https=) |
| WO (1) | WO2022019259A1 (https=) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CA2376596C (en) | 1999-06-25 | 2009-10-06 | Genentech, Inc. | Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies |
| ES2639222T5 (es) | 2000-10-06 | 2023-11-24 | Kyowa Kirin Co Ltd | Células que producen unas composiciones de anticuerpo |
| SI3466976T1 (sl) * | 2014-01-31 | 2021-12-31 | Daiichi Sankyo Company, Limited | Anti-her2 konjugat protitelesa-zdravila |
| JP6612738B2 (ja) | 2014-04-10 | 2019-11-27 | 第一三共株式会社 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| SG10201912173RA (en) | 2016-10-07 | 2020-02-27 | Daiichi Sankyo Co Ltd | Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate |
| BR112019011794A2 (pt) * | 2016-12-12 | 2019-10-29 | Daiichi Sankyo Co Ltd | composição farmacêutica, e, método terapêutico. |
| SG11202011243XA (en) | 2018-05-28 | 2020-12-30 | Daiichi Sankyo Co Ltd | Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate |
| CA3107417C (en) * | 2018-07-25 | 2023-10-17 | Daiichi Sankyo Company, Limited | Effective method for manufacturing antibody-drug conjugate |
-
2021
- 2021-07-19 EP EP21846150.7A patent/EP4183420A4/en active Pending
- 2021-07-19 JP JP2022537997A patent/JP7848119B2/ja active Active
- 2021-07-19 US US18/016,864 patent/US20230293714A1/en active Pending
- 2021-07-19 CN CN202180049952.0A patent/CN115884794A/zh active Pending
- 2021-07-19 IL IL300030A patent/IL300030A/en unknown
- 2021-07-19 AU AU2021312537A patent/AU2021312537A1/en active Pending
- 2021-07-19 WO PCT/JP2021/026932 patent/WO2022019259A1/ja not_active Ceased
- 2021-07-19 BR BR112023000982A patent/BR112023000982A2/pt unknown
- 2021-07-19 TW TW110126421A patent/TW202216214A/zh unknown
- 2021-07-19 KR KR1020237005605A patent/KR20230042055A/ko active Pending
- 2021-07-19 CA CA3186675A patent/CA3186675A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025041725A5 (https=) | ||
| JPWO2020122034A5 (https=) | ||
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2023070678A5 (https=) | ||
| JP2022101693A5 (https=) | ||
| JP2010535713A5 (https=) | ||
| JP2017186337A5 (https=) | ||
| JP2021515559A5 (https=) | ||
| JP2020502271A5 (https=) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| HRP20180262T1 (hr) | Monoklonska anti-gt468 protutijela za liječenje karcinoma | |
| JP2008531576A5 (https=) | ||
| JP2020514310A5 (https=) | ||
| JP2014522850A5 (https=) | ||
| RU2011111746A (ru) | Композиции рекомбинантных антител против рецептора эпидермального фактора роста | |
| HRP20240626T1 (hr) | Bispecifična antitijela protiv ceacam5 i cd3 | |
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| JP2009505676A5 (https=) | ||
| RU2009115363A (ru) | Антагонисты рецепторов для лечения метастатического рака | |
| JP2025092589A5 (https=) | ||
| JP2014502955A5 (https=) | ||
| JP2017522871A5 (https=) | ||
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| JPWO2021177438A5 (https=) | ||
| ME02296B (me) | Postupak za liječenje kancera dll4 antagonistom i hemoterapijskim agensom |